Published in Mol Ther on November 01, 2016
Advances in Non-Viral DNA Vectors for Gene Therapy. Genes (Basel) (2017) 0.75
Enhancement of lung gene delivery after aerosol: a new strategy using non-viral complexes with antibacterial properties. Biosci Rep (2017) 0.75
High mucin 5AC expression predicts adverse postoperative recurrence and survival of patients with clear-cell renal cell carcinoma. Oncotarget (2017) 0.75
Personalized or Precision Medicine? The Example of Cystic Fibrosis. Front Pharmacol (2017) 0.75
Bacterial biofilms: a common cause of persistent infections. Science (1999) 40.82
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol (1998) 8.45
Cystic fibrosis. N Engl J Med (2005) 8.09
Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell (1998) 6.72
Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J (2006) 6.34
Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science (2008) 6.28
Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest (2002) 5.94
Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther (1999) 4.65
Chronic obstructive pulmonary disease. Lancet (2012) 4.43
Airway mucus function and dysfunction. N Engl J Med (2010) 4.41
Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev (2006) 4.39
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis (2009) 4.27
Structure and function of the polymeric mucins in airways mucus. Annu Rev Physiol (2008) 3.63
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev (2008) 3.41
Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med (2010) 3.36
Role of CFTR in airway disease. Physiol Rev (1999) 3.33
Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J (2001) 3.18
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem (2001) 3.15
A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science (2012) 2.98
Barrier properties of mucus. Adv Drug Deliv Rev (2008) 2.84
Antibody diffusion in human cervical mucus. Biophys J (1994) 2.82
Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol (2006) 2.79
Micro- and macrorheology of mucus. Adv Drug Deliv Rev (2009) 2.54
Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet (2008) 2.33
Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev (2011) 2.23
Real-time multiple-particle tracking: applications to drug and gene delivery. Adv Drug Deliv Rev (2005) 2.21
Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc Natl Acad Sci U S A (2009) 2.13
Mucins, mucus, and sputum. Chest (2009) 2.09
Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med (2012) 2.03
Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem J (2002) 2.02
From mucins to mucus: toward a more coherent understanding of this essential barrier. Proc Am Thorac Soc (2004) 2.02
Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J Biol Chem (2003) 2.01
Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol (2006) 1.98
Analysis of fluorophore diffusion by continuous distributions of diffusion coefficients: application to photobleaching measurements of multicomponent and anomalous diffusion. Biophys J (1998) 1.95
Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest (2012) 1.85
Three-dimensional fluorescence recovery after photobleaching with the confocal scanning laser microscope. Biophys J (2003) 1.83
Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther (2006) 1.78
Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology (2000) 1.77
Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol (2001) 1.74
Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm Pharmacol Ther (2008) 1.72
Regulation of airway surface liquid volume and mucus transport by active ion transport. Proc Am Thorac Soc (2004) 1.64
Tracheobronchial air-liquid interface cell culture: a model for innate mucosal defense of the upper airways? Am J Physiol Lung Cell Mol Physiol (2008) 1.55
Treatment of airway mucus hypersecretion. Ann Med (2006) 1.55
The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials (2009) 1.54
A new role for bicarbonate in mucus formation. Am J Physiol Lung Cell Mol Physiol (2010) 1.52
Mucociliary tracheal transport rates in man. J Appl Physiol (1975) 1.50
Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulm Med (2009) 1.49
Revisited role for mucus hypersecretion in the pathogenesis of COPD. Eur Respir Rev (2010) 1.48
Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care (2007) 1.43
Human airway mucin glycosylation: a combinatory of carbohydrate determinants which vary in cystic fibrosis. Glycoconj J (2001) 1.40
Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science (1994) 1.38
Innate immunity in cystic fibrosis lung disease. J Cyst Fibros (2012) 1.38
Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces. J Immunol (2005) 1.38
Oxidative stress in COPD. Chest (2013) 1.37
Effect of pH, viscosity and ionic-strength changes on ciliary beating frequency of human bronchial explants. Clin Sci (Lond) (1983) 1.36
Measuring size distribution in highly heterogeneous systems with fluorescence correlation spectroscopy. Biophys J (2003) 1.36
Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am J Respir Crit Care Med (2000) 1.35
Developmental mucin gene expression in the human respiratory tract. Am J Respir Cell Mol Biol (1999) 1.32
Drug transfer through mucus. Adv Drug Deliv Rev (2001) 1.32
Characterization of particle translocation through mucin hydrogels. Biophys J (2010) 1.27
Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. J Clin Invest (2014) 1.26
Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev (2008) 1.25
Sputum viscosity in chronic bronchitis, bronchiectasis, asthma and cystic fibrosis. Biorheology (1972) 1.24
Role of the physiochemical properties of mucus in the protection of the respiratory epithelium. Eur Respir J (1992) 1.23
Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev (2008) 1.22
Mucus and MUC in asthma. Curr Opin Pulm Med (2006) 1.22
The physical properties of biogels and their permeability for macromolecular drugs and colloidal drug carriers. J Pharm Sci (2000) 1.20
Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev (2002) 1.17
Mucociliary clearance as an outcome measure for cystic fibrosis clinical research. Proc Am Thorac Soc (2007) 1.14
Mucin structure. The structure and heterogeneity of respiratory mucus glycoproteins. Am Rev Respir Dis (1991) 1.11
Respiratory alterations due to urban air pollution: an experimental study in rats. Environ Res (1992) 1.11
Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials (2013) 1.11
Relationship of airway epithelial ion transport to chronic bronchitis. Proc Am Thorac Soc (2004) 1.10
Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways. Mucosal Immunol (2012) 1.10
Biological hydrogels as selective diffusion barriers. Trends Cell Biol (2011) 1.10
Hyperviscous airway periciliary and mucous liquid layers in cystic fibrosis measured by confocal fluorescence photobleaching. FASEB J (2011) 1.07
Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv Mater (2012) 1.05
Airway surface liquid depth measured in ex vivo fragments of pig and human trachea: dependence on Na+ and Cl- channel function. Am J Physiol Lung Cell Mol Physiol (2009) 1.04
Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulm Pharmacol Ther (2006) 1.04
Collection and analysis of respiratory mucus from subjects without lung disease. Am Rev Respir Dis (1990) 1.04
Highly compacted DNA nanoparticles with low MW PEG coatings: in vitro, ex vivo and in vivo evaluation. J Control Release (2011) 1.03
A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease. PLoS One (2014) 1.03
Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J Control Release (2014) 1.03
IgG in cervicovaginal mucus traps HSV and prevents vaginal herpes infections. Mucosal Immunol (2014) 1.02
Bronchial mucus properties in lung cancer: relationship with site of lesion. Can Respir J (1999) 1.02
Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond) (2011) 1.01
The mechanism of mucus production in bronchial asthma. Curr Med Chem (2009) 1.00
Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients. PLoS One (2011) 0.99
Rheological properties of microliter quantities of normal mucus. J Appl Physiol Respir Environ Exerc Physiol (1977) 0.99
Mucoadhesive nanoparticles may disrupt the protective human mucus barrier by altering its microstructure. PLoS One (2011) 0.99
A study of macromolecular diffusion through native porcine mucus. Experientia (1992) 0.99
N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. Mol Ther (2011) 0.98
The Relationship of Mucus Concentration (Hydration) to Mucus Osmotic Pressure and Transport in Chronic Bronchitis. Am J Respir Crit Care Med (2015) 0.97
Cigarette smoke and CFTR: implications in the pathogenesis of COPD. Am J Physiol Lung Cell Mol Physiol (2013) 0.96
Regulated mucin secretion from airway epithelial cells. Front Endocrinol (Lausanne) (2013) 0.95
Oxidation increases mucin polymer cross-links to stiffen airway mucus gels. Sci Transl Med (2015) 0.95
Acidic pH increases airway surface liquid viscosity in cystic fibrosis. J Clin Invest (2016) 0.95
CFTR and lung homeostasis. Am J Physiol Lung Cell Mol Physiol (2014) 0.94
Establishment of respiratory air-liquid interface cultures and their use in studying mucin production, secretion, and function. Methods Mol Biol (2012) 0.93
Measurement of tracheal and bronchial mucus velocities in man: relation to lung clearance. J Appl Physiol Respir Environ Exerc Physiol (1980) 0.92